Having trouble viewing this email? View in your browser.
ESCMID Logo

2 July 2019
WEEKLY NEWS

Dear colleagues,

Please find below the latest edition of ESCMID Weekly News.

With kind regards,

ESCMID Executive Office.

 

ESCMID Research Grants 2020: apply now!

ESCMID Research Grants help young outstanding investigators pursue ground-breaking research in the fields of clinical microbiology and infectious diseases. The application period for ESCMID Research Grants 2020 is open! The submission deadline will be in September 2019 (the exact date will be communicated soon).

ATTENTION: For this call, only projects dealing with Bacterial Infections & Diseases (incl. diagnostics, pathogenesis, antibacterial susceptibility & resistance, antibacterial stewardship, vaccines) will be accepted. For further information click on this link and please also see the Research Grant FAQ.

› Read more

Late-breaking abstracts now being accepted for IMMEM XII

Have some cutting-edge research findings to share? Late-breaking abstracts are being accepted for inclusion in the 12th International Meeting on Microbial Epidemiological Markers (IMMEM XII), to be held in Dubrovnik, Croatia from 18-21 September 2019.
The theme of the meeting is “Moving towards genome-based pathogen surveillance – lessons learnt and challenges ahead”.

Find out more on the conference website!

› Read more

ESCMID Study Group Research Grants: the call is open!

In 2019, ESCMID will support Study Group research projects in the fields of clinical microbiology and infectious diseases. The call to apply for the ESCMID Study Group Research Grants is open and the deadline for submitting your applications is 17 July 2019, 17:00 CEST.
 All information regarding ESCMID Study Group Research funding is available here.

Please carefully read the updated “What you need to apply” section: important changes have been made compared to the previous call.

› Read more
 

Abstract Deadline - 5th ESCMID Conference on Vaccines

Scientists from all over the world get a last chance to share their work and submit their abstract via our easy-to-use platform until the 5th July 2019 – 23.59h CET. Don’t miss the chance to be part of this great conference and share your research insights with scientists from across the globe!

› Read more
 

ESCMID Summer School kicks off in Liverpool!

The 18th ESCMID Summer School started on Saturday in Liverpool, UK. This week-long course encompasses a myriad of topics across the areas of CM and ID in an informal environment, enabling great participant-faculty interaction.

Follow along on twitter with the hashtag #ESCMIDSummerSchool

› Read more
 

ECCMID 2019 donations: Thank You!

The mission of ESCMID is to promote research and education in the prevention, diagnosis and treatment of infections. To achieve these aims, the help of the ESCMID community is essential. This year ESCMID gave the possibility to speakers and chairs invited at ECCMID 2019 to donate a portion of their reimbursement to fund ESCMID ongoing scientific activities. We are deeply thankful to the ECCMID faculty members that contributed with their generous support to promote our initiatives. We thank you again for your contribution and we look forward to meeting you at ECCMID 2020 in Paris!

 

New CMI impact factor

Clinical Microbiology and Infection has a new impact factor of 6.425, an increase of 20% from last year. Congratulations to all editors and contributing authors for their contributions and commitment to the continued improvement of the society’s journal!

› Read more
 

New ESCMID Guideline: ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children

ESCMID would like to thank all the examiners that participate to a successful public consultation phase allowing the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM) to develop a paediatric specific guideline for the diagnosis and management of IA in neonates and children.This guideline provides recommendations for the diagnosis, prevention and treatment of IA in the paediatric population, including neonates. The aim of this guideline is to facilitate optimal management of neonates and children at risk for or diagnosed with IA.

› Read more
 

CMI Highlight: Characterization of antibody and memory T cell response in H7N9 survivors: A cross-sectional analysis

MJ. MA et al. Seek to understand why despite the importance of immunological memory for protective immunity against viral infection, whether H7N9-specific antibodies and memory T-cell responses remain detectable years after initial infection.

A cross-sectional study was conducted to investigate the immune memory responses of H7N9 patients who contracted the disease and survived during the 2013–2016 epidemics in China. Sustainability of antibodies and T-cell memory to H7N9 virus were examined. Healthy subjects receiving routine medical examination in physical examination center were recruited as control.

A total of 75 survivors were enrolled and classified into four groups based on the time elapsed from illness onset to specimen collection: three months (n=14), 14 months (n=14), 26 months (n=28), and 36 months (n=19). Approximately 36 months after infection, the geometric mean titers of virus-specific antibodies were significantly lower than titers in patients of three months after infection, but 16 of 19 (84.2%) survivors in the 36-month interval had microneutralization (MN) titer > 40. Despite the overall declining trend, the percentages of virus-specific cytokines-secreting memory CD4+ and CD8+ T-cells remained higher in survivors at nearly all time points in comparison with control subjects. Linear regression analysis showed that severe disease (mean titer ratio 2.77, 95%CI 1.17-6.49) was associated with higher hemagglutination inhibition (HI) titer, and female sex for both HI (1.92, 1.02-3.57) and MN (3.33, 1.26-9.09) antibody, whereas female sex (mean percentage ratio 1.69, 95%CI 1.08-2.63), underlying medical conditions (1.94, 95%CI 1.09-3.46), and lack of antiviral therapy (2.08, 95%CI 1.04-4.17) were predictors for higher T-cell responses.

Survivors from H7N9 virus infection produced long-term antibodies and memory T-cells responses. Our findings warrant further serological investigation in general and high-risk populations and have important implications for vaccine design and development.

› Read more
ESCMID Executive Office
P.O. Box 214
4010 Basel
Switzerland
Phone +41 61 5080 173
info@escmid.org
www.escmid.org
Follow ESCMID
Visit us on LinkedIn Visit us on YouTube
 
The ESCMID Newsletter is issued on behalf of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) by the ESCMID Executive Office. It contains announcements of ESCMID-related matters and other information of interest to professionals in the infection field.

Tip: To ensure that you receive the ESCMID newsletter in your inbox, add newsletter@escmid.org to your email program’s address book.

You have received this email as a contact of ESCMID or one of its affiliated societies. You can unsubscribe or change your newsletter subscriptions here.